Form 8-K - Current report:
SEC Accession No. 0001641489-26-000011
Filing Date
2026-03-10
Accepted
2026-03-10 16:35:39
Documents
14
Period of Report
2026-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20260310.htm   iXBRL 8-K 25713
2 EX-99.1 vtvt-20251231xexx991pressr.htm EX-99.1 99211
6 GRAPHIC newvtvimage30042424.jpg GRAPHIC 684980
  Complete submission text file 0001641489-26-000011.txt   1184214

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20260310.xsd EX-101.SCH 1794
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20260310_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20260310_pre.xml EX-101.PRE 12516
17 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20260310_htm.xml XML 2829
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

EIN.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 26739863
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)